Cargando…

Real-world analysis of cost, health care resource utilization, and supportive care in Hodgkin lymphoma patients with frontline failure

PURPOSE: The purpose of this study was to evaluate the economic burden of frontline failure (FLF) among classical Hodgkin lymphoma (HL) patients during and after treatment. PATIENTS AND METHODS: The population consisted of adult HL patients identified from January 2010 through September 2015 without...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bonafede, Machaon, Feliciano, Joseph, Cai, Qian, Noxon, Virginia, Princic, Nicole, Richhariya, Akshara, Straus, David J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198880/ https://www.ncbi.nlm.nih.gov/pubmed/30410373 http://dx.doi.org/10.2147/CEOR.S178649

Ejemplares similares

Medical costs associated with cardiovascular events among high-risk patients with hyperlipidemia
por: Bonafede, Machaon M, et al.
Publicado: (2015)

Real-World Health Care Resource Utilization and Costs Among US Patients with Knee Osteoarthritis Compared with Controls
por: Bedenbaugh, Angela V, et al.
Publicado: (2021)

Short- and longer-term health-care resource utilization and costs associated with acute ischemic stroke
por: Johnson, Barbara H, et al.
Publicado: (2016)

Care Among Migraine Patients in a Commercially Insured Population
por: Bonafede, Machaon, et al.
Publicado: (2020)

Patient-reported distress in Hodgkin lymphoma across the survivorship continuum
por: Troy, Jesse D., et al.
Publicado: (2018)

Healthcare utilization and cost of cancer-related care prior to allogeneic hematopoietic cell transplantation for hematologic malignancies in the US: a retrospective real-world analysis
por: Bonafede, Machaon, et al.
Publicado: (2021)

Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US
por: Bonafede, Machaon M, et al.
Publicado: (2013)

Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population
por: Bonafede, Machaon, et al.
Publicado: (2014)

Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
por: Bowen, James, et al.
Publicado: (2020)

Healthcare resource utilization and costs among children with cystic fibrosis in the United States
por: Thorat, Teja, et al.
Publicado: (2021)

Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera
por: Parasuraman, Shreekant V., et al.
Publicado: (2018)

Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors
por: Allen, Pamela B, et al.
Publicado: (2017)

Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA
por: Laliberté, François, et al.
Publicado: (2020)

Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data
por: Gharaibeh, Mahdi, et al.
Publicado: (2020)

Comorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adults
por: Polsky, Daniel, et al.
Publicado: (2012)

Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States
por: Thorat, Teja, et al.
Publicado: (2021)

Pegfilgrastim in Supportive Care of Hodgkin Lymphoma
por: Cerchione, Claudio, et al.
Publicado: (2022)

Patient-level costs of major cardiovascular conditions: a review of the international literature
por: Nicholson, Gina, et al.
Publicado: (2016)

Progress in understanding the biology of nodular lymphocyte-predominant Hodgkin lymphoma
por: Straus, David J.
Publicado: (2021)

Resources-Stratified Guidelines for Classical Hodgkin Lymphoma
por: Relecom, Allan, et al.
Publicado: (2020)

Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA
por: Bell, Christopher F, et al.
Publicado: (2020)

Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data
por: Paranagama, Dilan, et al.
Publicado: (2018)

Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic Syndromes
por: Mozessohn, Lee, et al.
Publicado: (2023)

Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting
por: Bonafede, Machaon, et al.
Publicado: (2013)

The direct and indirect costs of adult atopic dermatitis
por: Manjelievskaia, Janna, et al.
Publicado: (2021)

Real-World Evaluation of Direct and Indirect Economic Burden Among Endometriosis Patients in the United States
por: Soliman, Ahmed M., et al.
Publicado: (2018)

Real-World Analysis of Treatment Patterns, Healthcare Utilization, Costs, and Mortality Among People with Biliary Tract Cancers in the USA
por: Healey, Marcus J., et al.
Publicado: (2022)

Medication usage, treatment intensification, and medical cost in patients with type 2 diabetes: a retrospective database study
por: Bonafede, Machaon, et al.
Publicado: (2016)

Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis
por: Fox, Robert J., et al.
Publicado: (2022)

Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study
por: Pawaskar, Manjiri, et al.
Publicado: (2013)

Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis
por: Nelson, Winnie W, et al.
Publicado: (2021)

Time associated with intravenous zoledronic acid administration in patients with breast or prostate cancer and bone metastasis
por: Richhariya, Akshara, et al.
Publicado: (2012)

Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis
por: Bonafede, Machaon, et al.
Publicado: (2020)

Cost-Utility Analysis of IEV Drug Regimen Versus ESHAP Drug Regimen for the Patients With Relapsed and Refractory Hodgkin and Non-Hodgkin’s Lymphoma in Iran
por: Hatam, Nahid, et al.
Publicado: (2015)

Trends in quality of non-Hodgkin’s lymphoma care: is it getting better?
por: Stienen, J. J. C., et al.
Publicado: (2015)

PB2160: ASSOCIATION OF BCL-2 EXPRESSING TUMOR CELLS WITH RESPONSE TO FRONTLINE CHEMOTHERAPY IN NODULAR SCLEROSIS HODGKIN LYMPHOMA
por: Diakonov, D., et al.
Publicado: (2022)

Annual costs among patients with major depressive disorder and the impact of key clinical events
por: Cutler, Andrew J, et al.
Publicado: (2022)

Real‐World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B‐Cell Lymphoma in the U.S
por: Yang, Xiaoqin, et al.
Publicado: (2021)

Resource Utilization and Costs of Care prior to ART Initiation for Pediatric Patients in Zambia
por: Iyer, Hari S., et al.
Publicado: (2014)

COPD exacerbation frequency and its association with health care resource utilization and costs
por: Dhamane, Amol D, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_3r5fcldfl046pij5h4osg7uq5r